Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority

Basel, 16 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Sha re, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 7, 2019 (as it may be amended and supplemented from time to time, the “Offer”). The offering period of the Offer is scheduled to expire at 5:00 p.m., New York City time, on Monday, December 16, 2019, unless it is extended further under the circumstances set forth in the Agreement and Plan of Merger, dated as of February 22, 2019, by and among Roche Holdings, Inc., 022019 Merger Subsidiary, Inc., and Spark. Closing of the tender offer is conditioned upon customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and there being validly tendered and received, and not validly withdrawn, a majority of the outstanding Spark Shares. MacKenzie Partners, Inc. is acting as information agent for the Offer. Requests for documents and questions r...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: Available online 30 March 2020Source: Journal of Environmental PsychologyAuthor(s): Jonathon P. Schuldt, Peter K. Enns, Sara H. Konrath, Norbert Schwarz
Source: Journal of Environmental Psychology - Category: Psychiatry & Psychology Source Type: research
Most women who are notified by mail that they have a high risk of breast cancer are unlikely to do anything about it, a small study suggests.Reuters Health Information
Source: Medscape Radiology Headlines - Category: Radiology Tags: Hematology-Oncology News Source Type: news
In late February, Holiday Tours of Randleman celebrated taking delivery of its 100th and 101st bus built by Canadian bus builder Prevost. Officials from both companies were all smiles as they posed beside a bus with an award commemorating the occasion. This week, the 42-year-old family business temporarily closed its doors, furloughing its entire staff and all its drivers in the midst of the economic upheaval caused by coronavirus. Following Gov. Roy Cooper’s stay-at-home orders, Holiday Tours,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
ConclusionsOur study reveals the need for targeted patient ‐education about the benefits and limitations of follow‐up. In order to meet increasing costs of cancer care, individualized follow‐up procedures adjusted to risk of recurrence and late‐effects in cervical cancer survivors are warranted.
Source: Acta Obstetricia et Gynecologica Scandinavica - Category: OBGYN Authors: Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Radiation therapy vendor Varian Medical Systems has added new artificial intelligence...Read more on AuntMinnie.comRelated Reading: Varian gets FDA nod for Ethos adaptive therapy unit Varian posts strong Q1 sales growth as profit slips Varian installs systems in Africa, U.S. Varian awarded Mich. cancer software contract Varian posts continued revenue gains in Q4, fiscal 2019
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
The White House is expected to release models showing the future course of the disease, and the C.D.C. is reviewing its guidance on wearing masks as new data suggests many people with no symptoms are infecting others.
Source: NYT Health - Category: Consumer Health News Tags: Coronavirus (2019-nCoV) Trump, Donald J India United States China Source Type: news
Spark will continue its operations in Philadelphia as an independent company within the Roche Group             Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement. Commenting on this important step forward, Severin Schwan, CEO of Roche, said, “We are excited about this important milestone because we believe that together...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that Roche’s wholly owned subsidiary 022019 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Spark, at a price of USD 114.50 per share in ca sh.  The tender offer expired at 5:00 p.m., New York City time, on 16 December 2019 and was not extended. Roche has been advised by Citibank, N.A., the depositary for the tender offer, that a total of appr...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Biotechnology | Blindness | Brain | Canada Health | Cancer | Cancer & Oncology | Children | Diabetes | Endocrinology | Gene Therapy | Genetics | Haemophilia | Hemophilia | Hospitals | Infectious Diseases | International Medicine & Public Health | Japan Health | Mergers and Aquisitions | Neurology | Neuroscience | Opthalmology | Palliative | Pharmaceuticals | Science | Switzerland Health | Tax | USA Health | WHO